Sodium-dependent glucose transporter-2 (SGLT2) inhibitors are a new class of anti-diabetic
drugs, which increase urinary glucose excretion thereby promoting weight loss and decreasing
plasma glucose levels. We hypothesize that the pharmacodynamic response to SGLT2 inhibitors
(specifically canagliflozin) varies among individuals, and that a proportion of this
inter-individual variation can be explained by genetic variation. This is a pilot study in
healthy, non-diabetic subjects in whom glucose and other related metabolites in the urine and
plasma will be measured before and after administration of a single dose of canagliflozin.
This will allow us to characterize the inter-individual variation in the pharmacodynamic
response to canagliflozin as well as determine if changes in glucose and other related
metabolite levels are associated with variants in various candidate genes.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)